Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment

Current Heart Failure Reports

Volumn 15, Issue 1, 2018, Pages 10-16

  Samman Tahhan, Ayman ^a   Vaduganathan, Muthiah ^b   Greene, Stephen J ^c   Okafor, Maureen ^a   Kumar, Sonali ^a   Butler, Javed ^d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d STONY BROOK UNIVERSITY   (United States)

Author keywords

Clinical trials; Endpoints; Enrollment; Heart failure; Temporal trends

Indexed keywords

CARDIOVASCULAR MORTALITY; CLINICAL OUTCOME; DEVELOPING COUNTRY; DRUG DEVELOPMENT; EMERGENCY WARD; FUNCTIONAL STATUS; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HOSPITALIZATION; HUMAN; PATIENT CARE; PRACTICE GUIDELINE; PREVALENCE; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOCIAL STATUS; SYSTEMATIC REVIEW (TOPIC); BIOASSAY; CLINICAL TRIAL (TOPIC); HEART FAILURE; HEART STROKE VOLUME; ORGANIZATION AND MANAGEMENT; PATHOPHYSIOLOGY; PATIENT SELECTION; PHYSIOLOGY;

CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; HEART FAILURE; HUMANS; PATIENT SELECTION; STROKE VOLUME;

EID: 85040644578     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-018-0374-z     Document Type: Review

References (47)

1. Neuman MD, Goldstein JN, Cirullo MA, Schwartz JS. Durability of class I American College of Cardiology/American Heart Association clinical practice guideline recommendations. JAMA. 2014;311(20):2092–100. https://doi.org/10.1001/jama.2014.4949.
2. •• Gheorghiade M, Vaduganathan M, Greene SJ, Mentz RJ, Adams KF Jr, Anker SD, et al. Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. Heart Fail Rev. 2014;19:135–52. This analysis of more than 150 heart failure trials published in major journals between 2001-2012 provides details on enrollment rates and key trial-level characteristics.
3. Greene SJ, Shah AN, Butler J, Ambrosy AP, Anker SD, Chioncel O, et al. Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. Am Heart J. 2014;168(2):142–9. https://doi.org/10.1016/j.ahj.2014.05.009.
4. • Baldi ILC, Berchialla P, Gregori D. Early termination of cardiovascular trials as a consequence of poor accrual: analysis of ClinicalTrials.gov 2006–2015. BMJ Open. 2017;7:e013482. This is a recent analysis of ClinicalTrials.gov database which showed that poor accrual was the most common reason for trials failing to complete.
5. •• Samman Tahhan A, Vaduganathan M, Kelkar A, Georgiopoulou VV, Kalogeropoulos AP, Greene SJ, et al. Trends in heart failure clinical trials from 2001-2012. J Card Fail. 2016;22(3):171–9. https://doi.org/10.1016/j.cardfail.2015.06.014. This analysis of more than 150 heart failure trials published in major journals between 2001-2012 provides details on enrollment rates and key trial-level characteristics.
6. • Butler J, Tahhan AS, Georgiopoulou VV, Kelkar A, Lee M, Khan B, et al. Trends in characteristics of cardiovascular clinical trials 2001-2012. Am Heart J. 2015;170(2):263–72. https://doi.org/10.1016/j.ahj.2015.05.006. This analysis of more than 1200 published cardiovascular clinical trials provides trends in enrollment rates, trial duration, geographic distribution, funding mechanisms and trials outcomes.
7. • Butler J, Subacius H, Vaduganathan M, Fonarow GC, Ambrosy AP, Konstam MA, et al. Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. J Am Coll Cardiol. 2013;61(5):571–9. https://doi.org/10.1016/j.jacc.2012.10.025. This analysis from EVERST trial showed that the enrollment rate differed between sites and was associated with participant characteristics and outcomes.
8. •• Greene SJ, Hernandez AF, Sun JL, Metra M, Butler J, Ambrosy AP, et al. Influence of clinical trial site enrollment on patient characteristics, protocol completion, and end points: insights from the ASCEND-HF trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). Circ Heart Fail. 2016;9(9):e002986. https://doi.org/10.1161/CIRCHEARTFAILURE.116.002986. Using ASCEND-HF data, this analysis demonstrated the impact of variable site enrollment on clinical end points of the trial.
9. Gul RB, Ali PA. Clinical trials: the challenge of recruitment and retention of participants. J Clin Nurs. 2010;19(1-2):227–33. https://doi.org/10.1111/j.1365-2702.2009.03041.x.
10. Chang BH, Hendricks AM, Slawsky MT, Locastro JS. Patient recruitment to a randomized clinical trial of behavioral therapy for chronic heart failure. BMC Med Res Methodol. 2004;4(1):8. https://doi.org/10.1186/1471-2288-4-8.
11. Galbreath AD, Smith B, Wood P, Forkner E, Peters JI. Cumulative recruitment experience in two large single-center randomized, controlled clinical trials. Contemp Clin Trials. 2008;29(3):335–42. https://doi.org/10.1016/j.cct.2007.10.002.
12. Campbell MK, Snowdon C, Francis D, Elbourne D, McDonald AM, Knight R, et al. Recruitment to randomised trials: strategies for trial enrollment and participation study. The STEPS study. Health Technol Assess. 2007;11:iii. ix-105
13. • Harinstein ME, Butler J, Greene SJ, Fonarow GC, Stockbridge NL, O'Connor CM, et al. Site selection for heart failure clinical trials in the USA. Heart Fail Rev. 2015;20(4):375–83. https://doi.org/10.1007/s10741-015-9473-z. This paper describes various barriers to participation in hospitalized heart failure trials in the US.
14. Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, et al. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail. 2013;15(10):1082–94. https://doi.org/10.1093/eurjhf/hft095.
15. Okumura N, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, et al. Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Circulation. 2016;133(23):2254–62. https://doi.org/10.1161/CIRCULATIONAHA.115.020729.
16. Butler J, Braunwald E, Gheorghiade M. Recognizing worsening chronic heart failure as an entity and an end point in clinical trials. JAMA. 2014;312(8):789–90. https://doi.org/10.1001/jama.2014.6643.
17. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875–85. https://doi.org/10.1016/S0140-6736(10)61198-1.
18. Shen L, Jhund PS, Mogensen UM, Kober L, Claggett B, Rogers JK, et al. Re-examination of the BEST trial using composite outcomes, including emergency department visits. JACC Heart Fail. 2017;5(8):591–9. https://doi.org/10.1016/j.jchf.2017.04.005.
19. Solomon SD, Rizkala AR, Gong J, Wang W, Anand IS, Ge J, et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial. JACC Heart Fail. 2017;5(7):471–82. https://doi.org/10.1016/j.jchf.2017.04.013.
20. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365(1):32–43. https://doi.org/10.1056/NEJMoa1100171.
21. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381(9860):29–39. https://doi.org/10.1016/S0140-6736(12)61855-8.
22. • Vaduganathan M, Greene SJ, Ambrosy AP, Gheorghiade M, Butler J. The disconnect between phase II and phase III trials of drugs for heart failure. Nat Rev Cardiol. 2013;10(2):85–97. https://doi.org/10.1038/nrcardio.2012.181. This review highlights the disconnect between phase II and phase III heart failure trials and provides common themes from noted in five drug development programs.
23. •• Vaduganathan M, Samman Tahhan A, Greene SJ, Okafor M, Kumar S, Butler J. Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years. Eur J Heart Fail. 2018. https://doi.org/10.1002/ejhf.1130. This is a recent article that describes patterns of rapid globalization of more than 300 heart failure clinical trials published from 2001-2016.
24. Lang T, Siribaddana S. Clinical trials have gone global: is this a good thing? PLoS Med. 2012;9(6):e1001228. https://doi.org/10.1371/journal.pmed.1001228.
25. MacMahon S, Perkovic V, Patel A. Industry-sponsored clinical trials in emerging markets: time to review the terms of engagement. JAMA. 2013;310(9):907–8. https://doi.org/10.1001/jama.2013.276913.
26. Ferreira JP, Girerd N, Rossignol P, Zannad F. Geographic differences in heart failure trials. Eur J Heart Fail. 2015;17(9):893–905. https://doi.org/10.1002/ejhf.326.
27. Greene SJ, Gheorghiade M. Same protocol, different continents, different patients: should we continue to conduct global heart failure trials? Eur J Heart Fail. 2015;17(9):875–8. https://doi.org/10.1002/ejhf.335.
28. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383–92. https://doi.org/10.1056/NEJMoa1313731.
29. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131(1):34–42. https://doi.org/10.1161/CIRCULATIONAHA.114.013255.
30. Bristow MR, Enciso JS, Gersh BJ, Grady C, Rice MM, Singh S, et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC Basic Transl Sci. 2016;1(3):180–9. https://doi.org/10.1016/j.jacbts.2016.03.001.
31. de Denus S, O'Meara E, Desai AS, Claggett B, Lewis EF, Leclair G, et al. Spironolactone metabolites in TOPCAT—new insights into regional variation. N Engl J Med. 2017;376(17):1690–2. https://doi.org/10.1056/NEJMc1612601.
32. • Vaduganathan M, Samman-Tahhan A, Patel RB, Kelkar A, Papadimitriou L, Georgiopoulou VV, et al. Association between funding sources and the scope and outcomes of cardiovascular clinical trials: a systematic review. Int J Cardiol. 2017;230:301–3. https://doi.org/10.1016/j.ijcard.2016.12.119. This systematic review describes differences in trial characteristics including design, intervention, enrollment rates and outcomes stratified by funding mechanism.
33. Ridker PM, Torres J. Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. JAMA. 2006;295(19):2270–4. https://doi.org/10.1001/jama.295.19.2270.
34. Hopewell S, Loudon K, Clarke MJ, Oxman AD and Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev. 2009:MR000006.
35. Montgomery JH, Byerly M, Carmody T, Li B, Miller DR, Varghese F, et al. An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Control Clin Trials. 2004;25(6):598–612. https://doi.org/10.1016/j.cct.2004.09.002.
36. Bhandari M, Busse JW, Jackowski D, Montori VM, Schunemann H, Sprague S, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ: Can Med Assoc J = journal de l'Association medicale canadienne. 2004;170:477–80.
37. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326(7400):1167–70. https://doi.org/10.1136/bmj.326.7400.1167.
38. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012;126(1):65–75. https://doi.org/10.1161/CIRCULATIONAHA.111.080770.
39. Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail. 2011;13(1):18–28. https://doi.org/10.1093/eurjhf/hfq121.
40. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14(10):591–602. https://doi.org/10.1038/nrcardio.2017.65.
41. Kelly JP, Mentz RJ, Mebazaa A, Voors AA, Butler J, Roessig L, et al. Patient selection in heart failure with preserved ejection fraction clinical trials. J Am Coll Cardiol. 2015;65(16):1668–82. https://doi.org/10.1016/j.jacc.2015.03.043.
42. Anand IS, Claggett B, Liu J, Shah AM, Rector TS, Shah SJ, et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC Heart Fail. 2017;5(4):241–52. https://doi.org/10.1016/j.jchf.2016.11.015.
43. Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H, et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail. 2011;4(5):569–77. https://doi.org/10.1161/CIRCHEARTFAILURE.111.962654.
44. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–239. https://doi.org/10.1016/j.jacc.2013.05.019.
45. Heart Failure Society of America, Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;16:e1–194.
46. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–847.
47. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803–69.